{"id":48400,"date":"2022-09-14T20:01:46","date_gmt":"2022-09-14T18:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/"},"modified":"2022-09-14T20:01:46","modified_gmt":"2022-09-14T18:01:46","slug":"independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/","title":{"rendered":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses"},"content":{"rendered":"
\n

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers<\/a>–A group of distinguished Alzheimer\u2019s disease researchers has affirmed, in a new study published online in the journal Brain<\/i>, the superiority of the methods that are the basis of C2<\/sub>N Diagnostics\u2019 new p[hospho]-tau217 ratio test<\/a>. Currently available as a unique research tool in Alzheimer\u2019s clinical studies, C2<\/sub>N\u2019s p-tau217 ratio test is nearing completion of development as a clinical lab test that will help healthcare providers better diagnose Alzheimer\u2019s disease, particularly when combined with amyloid beta (A\u03b2) measures from C2<\/sub>N\u2019s existing PrecivityAD\u2122 clinical blood test<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nThe head-to-head comparison measured the diagnostic performance of 10 different tests that quantify plasma phosphorylated-tau concentrations, including the methods underlying C2<\/sub>N\u2019s p-tau217 ratio blood test, to detect abnormal brain amyloid-\u03b2 status and predict future progression to Alzheimer’s dementia. The different tests compared in the round-robin study ranged from using mass spectrometry (MS)-based methods to immunoassays to detect one of three phosphorylated tau markers, including p-tau181, p-tau217, and p-tau231.\n<\/p>\n

\nThe article, titled \u201cHead-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease<\/a>,\u201d explained that the study involved 135 patients with \u201cbaseline diagnosis of mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average of 4.9 years.\u201d The research team explained that it \u201cfound that the mass spectrometry-based p-tau217 [from Dr. Bateman at Washington University] exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal A\u03b2 status (AUC = 0.947; pdiff < 0.015) or progression to Alzheimer’s dementia (AUC = 0.932; pdiff < 0.027).\u201d Dr. Randall Bateman is a scientific co-founding member of C2<\/sub>N Diagnostics.\n<\/p>\n

\nThe C2<\/sub>N p-tau Multi-Analyte Assay (p-tau MAA<\/a>) blood test, which contains the p-tau217 ratio measurement, is underpinned by the MS assay that Dr. Bateman and his team developed at Washington University. C2<\/sub>N, under a technology transfer agreement with Washington University, optimized those methods and commercialized the p-tau MAA as a Research Use Only tool for use in Alzheimer\u2019s clinical research. At this year\u2019s AAIC annual meeting, the company reported<\/a> its first clinical research experience combining its p-tau217 ratio blood test with its A\u03b2 42\/40 ratio blood test to identify amyloid pathology in individuals with cognitive impairment or dementia. The integration of these two measures into a single score resulted in a test that achieved an AUC performance of 0.96 and accuracy of 90% when compared with quantitative amyloid PET results to identify the presence of brain amyloid plaques.\n<\/p>\n

\nThe researchers from the new round robin study further stated that \u201cmass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain A\u03b2 or those who will subsequently progress to Alzheimer’s dementia. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of A\u03b2-PET and CSF.\u201d A possible explanation for this may be that MS-based detection methods are highly accurate and potentially more so than immunoassays. Therefore, they could more reliably quantify low abundance proteins like p-tau protein forms and also A\u03b2 in protein-rich matrices such as blood.\n<\/p>\n

\nDr. Joel Braunstein, C2<\/sub>N president and CEO, says, \u201cThis latest research is an important finding that adds to other independent studies<\/a> that have demonstrated remarkable performance of our proprietary blood testing methods. It is clear from these studies that the specific type of assay used and biomarker measured matters when the goal is to reliably detect brain pathology among individuals experiencing cognitive impairment. This data will enable health care providers to make more informed decisions as they consider which blood-based biomarker tests to incorporate into the memory care of their patients in the future.\u201d\n<\/p>\n

\nAbout C2<\/sub>N Diagnostics, LLC<\/b>\n<\/p>\n

\nC2<\/sub>N<\/i> Diagnostics is a leader in advanced brain health diagnostics with a vision to bring Clarity Through Innovation\u2122. C2<\/sub>N strives to provide exceptional laboratory services and products in the field of brain health. C2<\/sub>N\u2019s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit <\/i>www.C2N.com<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA:
\n
Adam Shapiro
\n
Adam.Shapiro@ASPR.bz<\/a>
202-427-3603\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ST. LOUIS–(BUSINESS WIRE)–#Alzheimers–A group of distinguished Alzheimer\u2019s disease researchers has affirmed, in a new study published online in the journal Brain, the superiority of the methods that are the basis of C2N Diagnostics\u2019 new p[hospho]-tau217 ratio test. Currently available as a unique research tool in Alzheimer\u2019s clinical studies, C2N\u2019s p-tau217 ratio test is nearing completion … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48400","6":"format-standard","7":"category-industry"},"yoast_head":"\nIndependent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ST. LOUIS–(BUSINESS WIRE)–#Alzheimers–A group of distinguished Alzheimer\u2019s disease researchers has affirmed, in a new study published online in the journal Brain, the superiority of the methods that are the basis of C2N Diagnostics\u2019 new p[hospho]-tau217 ratio test. Currently available as a unique research tool in Alzheimer\u2019s clinical studies, C2N\u2019s p-tau217 ratio test is nearing completion ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T18:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses\",\"datePublished\":\"2022-09-14T18:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/\"},\"wordCount\":747,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005834\\\/en\\\/1571990\\\/21\\\/Picture1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/\",\"name\":\"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005834\\\/en\\\/1571990\\\/21\\\/Picture1.jpg\",\"datePublished\":\"2022-09-14T18:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005834\\\/en\\\/1571990\\\/21\\\/Picture1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005834\\\/en\\\/1571990\\\/21\\\/Picture1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/","og_locale":"en_US","og_type":"article","og_title":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend","og_description":"ST. LOUIS–(BUSINESS WIRE)–#Alzheimers–A group of distinguished Alzheimer\u2019s disease researchers has affirmed, in a new study published online in the journal Brain, the superiority of the methods that are the basis of C2N Diagnostics\u2019 new p[hospho]-tau217 ratio test. Currently available as a unique research tool in Alzheimer\u2019s clinical studies, C2N\u2019s p-tau217 ratio test is nearing completion ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-14T18:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses","datePublished":"2022-09-14T18:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/"},"wordCount":747,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/","url":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/","name":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg","datePublished":"2022-09-14T18:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220914005834\/en\/1571990\/21\/Picture1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/independent-research-finds-underlying-method-for-c2ns-p-tau217-ratio-blood-test-outperforms-other-tau-blood-tests-used-for-alzheimers-diagnoses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Independent Research Finds Underlying Method for C2N\u2019s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer\u2019s Diagnoses"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48400"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48400\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}